SCHEMBL4070374

SCHEMBL4070374

N#Cc1ccc(CNC2CCCc3cccnc32)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 2/20 0.64
HDAC6 Q9UBN7 2/20 0.64
CXCR4 P61073 6/20 0.44
KDM4E B2RXH2 3/20 0.42
ALDH1A1 P00352 3/20 0.41
LMNA P02545 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
KDM1A O60341 1/20 0.41
MAOA P21397 1/20 0.41
MAOB P27338 1/20 0.41
CYP2D6 P10635 4/20 0.39
CYP3A4 P08684 3/20 0.39
DHODH Q02127 1/20 0.38
JAK2 O60674 1/20 0.37
JAK1 P23458 1/20 0.37
TYK2 P29597 1/20 0.37
JAK3 P52333 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13909820 0.90 HDAC1 (0.76) HDAC1HDAC6CXCR4KDM4EALDH1A1
SCHEMBL3373416 0.87 HDAC1 (0.55) HDAC1HDAC6CXCR4KDM4EALDH1A1
SCHEMBL4562865 0.85 HDAC1 (0.69) HDAC1HDAC6CXCR4KDM4EALDH1A1
SCHEMBL4887341 0.85 HDAC1 (0.69) HDAC1HDAC6CXCR4KDM4EALDH1A1
SCHEMBL4065807 0.84 HDAC1 (0.68) HDAC1HDAC6CXCR4KDM4EALDH1A1
SCHEMBL21055028 0.84 HDAC1 (0.68) HDAC1HDAC6CXCR4KDM4EALDH1A1
SCHEMBL31064876 0.82 HDAC1 (0.54) HDAC1HDAC6CXCR4ALDH1A1LMNA
SCHEMBL2082282 0.82 HDAC1 (0.54) HDAC1HDAC6CXCR4KDM4EALDH1A1
SCHEMBL5575215 0.81 HDAC1 (0.65) HDAC1HDAC6CXCR4KDM4EALDH1A1
SCHEMBL14037709 0.81 HDAC1 (0.64) HDAC1HDAC6CXCR4KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1317445-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2009-03-11 EP disclosed
US-7396840-B2 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION (US) 2008-07-08 US disclosed
US-7084155-B2 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2006-08-01 US disclosed
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2006-06-15 US disclosed
US-6864265-B2 Chemokine receptor binding heterocyclic compounds ANORMED, INC. (CA) 2005-03-08 US disclosed
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2004-11-04 US disclosed
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2003-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220207-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 HDAC1 1111/4885HDAC6 805/4885CXCR4 7/4885
US-20060128750-A1 Chemokine receptor binding heterocyclic compounds CXCR4, CCR5, CXCR3 HDAC1 845/4885HDAC6 828/4885CXCR4 1/4885
US-20030018046-A1 Chemokine receptor binding heterocyclic compounds CXCR3, ACKR3, CCR2 HDAC1 1111/4885HDAC6 805/4885CXCR4 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.